Boston & New England CRE News In Your Inbox.

Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.

Sub Markets

Property Sectors


Boston & New England  + Boston  + Office  | 
Vertex Pharmaceuticals is building a 344,000-square-foot expansion of the Jeffrey Leiden Center for Cell and Genetic Therapies I in Boston’s Seaport.

Vertex Announces Expansion in Boston’s Seaport on Heels of Facility Dedication

Vertex Pharmaceuticals Incorporated has announced plans to build a 344,000-square-foot facility in Boston’s Seaport. When completed in 2025, Vertex will occupy 1.9 million square feet of real estate in the Seaport across five sites, making it the largest biotech in Boston in terms of square footage.

The new site, located on Drydock Avenue, will be an expansion of the newly dedicated Jeffrey Leiden Center for Cell and Genetic Therapies I on Northern Avenue. The new building will house labs, offices and manufacturing capabilities for approximately 500 additional employees.

The expansion is being developed in partnership with Related Beal, Boston Real Estate Inclusion Fund and Kavanagh Advisory group. Once this facility is complete, the two buildings will be known as the Leiden Campus.

Vertex and the Vertex Foundation also announced a $50-million commitment to health equity focused on clinical trial diversity, access to quality care and education of the local health care workforce.


Inside The Story

Vertex Pharmaceuticals Incorporated

About Lisa McDuffie

Lisa McDuffie arrives at ConnectCRE via REALTOR® world, where she served for nearly two decades as communications director for one of the nation’s largest REALTOR® organizations. She supported two membership-elected presidents who were commercial real estate practitioners, and managed the communications initiatives of the organization’s commercial special interest group. When not following the latest commercial real estate news, Lisa is zeroed in on her charismatic off-the-track thoroughbred as she makes the transition from an utterly failed racehorse to a lovely show hunter.

  • ◦Development